SCHEMBL3000884

SCHEMBL3000884

O=C(Oc1cc(OC(=O)c2cc(O)c(O)c(O)c2)c2ccccc2c1)c1cc(O)c(O)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 3/20 0.62
NSD2 O96028 1/20 0.60
POLB P06746 4/20 0.49
POLA1 P09884 1/20 0.49
ANTXR2 P58335 1/20 0.49
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
MAPT P10636 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
ALOX5 P09917 2/20 0.45
PTGES O14684 1/20 0.45
SELL P14151 1/20 0.43
SELP P16109 1/20 0.43
GAA P10253 3/20 0.42
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
JAK2 O60674 1/20 0.42
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30821431 1.00 SERPINE1 (0.62) SERPINE1NSD2POLBPOLA1ANTXR2
SCHEMBL3000109 0.91 SERPINE1 (0.51) SERPINE1NSD2POLBPOLA1ANTXR2
SCHEMBL3006064 0.89 SERPINE1 (0.48) SERPINE1NSD2POLBPOLA1ANTXR2
SCHEMBL2995722 0.88 KMT2A (0.47) SERPINE1NSD2POLBKMT2AMEN1
SCHEMBL2991316 0.87 SERPINE1 (0.45) SERPINE1NSD2POLBKMT2AMEN1
SCHEMBL3005674 0.83 SERPINE1 (0.77) SERPINE1NSD2POLBPOLA1ANTXR2
SCHEMBL4736134 0.80 KMT2A (0.70) SERPINE1NSD2POLBPOLA1ANTXR2
SCHEMBL3005870 0.80 SERPINE1 (0.77) SERPINE1NSD2POLBPOLA1ANTXR2
SCHEMBL2788238 0.78 SERPINE1 (1.00) SERPINE1NSD2POLBPOLA1ANTXR2
SCHEMBL30257503 0.78 NSD2 (0.71) SERPINE1NSD2POLBPOLA1ANTXR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210137934-A1 METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2021-05-13 US claimed
WO-2018170316-A1 METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2018-09-20 WO claimed
US-20100190856-A1 Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors UNIVERSIDAD COMPLUTENSE DE MADRID (ES) 2010-07-29 US claimed
EP-2019091-A1 Novel polyhydroxylated compounds as Fatty Acid Synthase (FASN) inhibitors Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) 2009-01-28 EP claimed
US-20210137934-A1 METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2021-05-13 US disclosed
WO-2018170316-A1 METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2018-09-20 WO disclosed
US-20100190856-A1 Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors UNIVERSIDAD COMPLUTENSE DE MADRID (ES) 2010-07-29 US disclosed
US-20100190856-A1 Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors UNIVERSIDAD COMPLUTENSE DE MADRID (ES) 2010-07-29 US disclosed
US-20100190856-A1 Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors UNIVERSIDAD COMPLUTENSE DE MADRID (ES) 2010-07-29 US disclosed
EP-2019091-A1 Novel polyhydroxylated compounds as Fatty Acid Synthase (FASN) inhibitors Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) 2009-01-28 EP disclosed
EP-2019091-A1 Novel polyhydroxylated compounds as Fatty Acid Synthase (FASN) inhibitors Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta (ES) 2009-01-28 EP disclosed
WO-2009000864-A1 NOVEL POLYHYDROXYLATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE GIRONA DR. JOSEP TRUETA (ES) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190856-A1 Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors FASN, SCD, FADS2 SERPINE1 1776/4885NSD2 4060/4885POLB 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.